An Introduction to Sarcoma
Sarcomas are a heterogeneous group of mesenchymal malignancies, with more than 50 subtypes identified. Until recently treatment was limited to standard chemotherapy regimens, however, advances in next-generation sequencing technology have led to the development of molecularly targeted therapy and immunotherapy that offer a personalized treatment approach.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Early recognition and emerging therapies for epithelioid sarcoma
Watch an international sarcoma expert discuss the diagnosis of and developing treatment options for epithelioid sarcoma, a rare sarcoma subtype.
- Recognize the challenges in the diagnosis and treatment of advanced epithelioid sarcoma
- Discuss the importance of SMARCB1 alterations, INI1 loss and other molecular changes in the diagnosis and treatment of patients with epithelioid sarcoma
- Outline the efficacy and safety of current and emerging targeted therapies in patients with epithelioid sarcoma
Pexidartinib and CSF1R Inhibitors as Treatment for Tenosynovial Giant Cell Tumors
Oncology & Hematology Review (US). 2020;16(2):119-23 DOI: https://doi.org/10.17925/OHR.2021.16.2.119
Tenosynovial giant cell tumor (TGCT)—previously referred to as giant cell tumor of the tendon sheath or pigmented villonodular synovitis (PVNS)—is a largely benign, rare, proliferative lesion arising from the synovial lining of joints, bursae, and tendon sheaths.1 This review serves to discuss the epidemiology, molecular biology, clinical behavior, and the current treatment modalities of TGCT that […]
Pazopanib in Soft Tissue Sarcomas
Oncology & Hematology Review (US). 2020;16(1):15–6 DOI: https://doi.org/10.17925/OHR.2020.16.1.15
Soft tissue sarcomas represent a group of over 80 rare malignant tumors that arise from tissues of mesenchymal origin throughout the body.1 Advanced soft tissue sarcoma is treated with single-agent or combination systemic chemotherapy, but is associated with a poor prognosis.2,3 Pazopanib (Votrient,® Novartis, Basel, Switzerland) is an oral multitarget tyrosine kinase inhibitor that has received regulatory as […]
Brian Van Tine, ESMO 2019 – Pazopanib in soft tissue sarcomas
Brain Van Tine (Washington University in St Louis) joins us to discuss the results of the phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy (NCT02300545). Questions 1. What are the limitations of standard first-line chemotherapy in the treatment of soft […]
Alona Zer, ASCO 2019 – Phase II study of nivolumab and ipilimumab in CKS
At the ASCO 2019 annual meeting, Alona Zer discusses the preliminary results from the interim analysis of a phase II study of nivolumab and ipilimumab in previously treated progressive Classic Kaposi Sarcoma (CKS) (NCT03219671). Questions 1. Could you tell us a little about Classic Kaposi Sarcoma (CKS) and its prognosis? (0:04) 2. What is the […]
Advanced soft tissue sarcoma – how can we address current controversies to solve a dilemma in clinical decision making?
Watch a panel of internationally renowned experts discuss the factors influencing the choice of first-line treatment for patients with advanced soft tissue sarcoma and the interpretation of data from clinical trials in this patient population.
- Describe first-line treatment options for patients with advanced soft tissue sarcoma (STS)
- Understand how patient selection may affect treatment choice and outcome in advanced STS
- Discuss how surrogate markers can be used in trial design to assess treatment outcomes in advanced STS
Development of Checkpoint Inhibitors for Sarcomas
Oncology & Hematology Review, 2017;13(1):25–9 DOI: https://doi.org/10.17925/OHR.2017.13.01.25
Sarcomas consist of a highly diverse group of malignancies of mesenchymal origin, encompassing more than 80 distinct subtypes and diagnosed in approximately 15,000 patients every year in the US.1 Surgery still represents the mainstay of therapy for patients with localized disease. Although the use of multimodal treatment with curative intent remains debatable in soft tissue […]
Monophasic Synovial Sarcoma of the Infratemporal Fossa—Case Report and Review of the Literature
Oncology & Hematology Review, 2017;13(1):56-8. DOI: https://doi.org/10.17925/OHR.2017.13.01.01
Synovial sarcoma (SS) is a malignant soft tissue tumor, which represents about 10% of all soft tissue sarcomas.1 It occurs most often in the lower extremities of young men, and is very rare in the head and neck region, with an incidence of about 2–4%.2,3 The origin of the SS remains uncertain, although it is […]
Radiotherapy Controversies in the Radical Treatment of Soft-tissue Sarcomas of the Limb
European Oncology & Haematology, 2013;9(1):42-5 DOI: https://doi.org/10.17925/EOH.2013.09.1.42
Soft-tissue sarcomas (STSs) should be managed by multidisciplinary teams, including specialist surgeons, radiation oncologists, medical oncologists, pathologists and radiologists. The aim of radical treatment for any STS should be to achieve the best possible local control rates with as little treatment-related morbidity and adverse effect on quality of life, as possible. Combination surgery and radiotherapy […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!